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Key questions
What is already known about this subject?
 ► Although more women are entering the global work-
force, this participation has not translated to full par-
ticipation at the upper management levels, including 
in the field of medical oncology. Leadership posi-
tions within oncology, such as presidents or board 
members of oncology societies and invited speakers 
at oncology congresses, remain predominantly held 
by men. Information remains sparse regarding the 
actual number of women participating in oncology 
societies and holding leadership positions in Europe, 
Asia Pacific and South America.
What does this study add?
 ► This publication provides recent figures for the 
percentage of women occupying leadership roles 
across a selected cohort of international and national 
European, South American and Asian large oncology 
societies and congresses, as well as direct compari-
sons between major US-based and European-based 
international societies and congresses. The data dis-
cussed here also suggest why gender gaps still exist 
and speculate how to achieve a better gender parity. 
Examples are given of successful programmes ad-
dressing this issue, and suggestions for new ways 
to provide resources and support to aid women in 
achieving their potential.
AbstrAct
Background While the global workforce is approaching 
gender parity, women occupy a small number of 
management level positions across most professions, 
including healthcare. Although the inclusion of women into 
the membership of many oncology societies has increased, 
the under-representation of women in leadership roles 
within international and national oncology societies 
remains relatively consistent. Moreover, the exact status of 
women participating as board members or presidents of 
oncology societies or as speakers at oncology congresses 
was undocumented to date.
Methods The database used in this analysis was derived 
from data collection performed by the European Society 
for Medical Oncology for the years 2015–2016 and data 
analyses performed using the Statistical Analysis Software 
V.9.3 and R language for statistical computing V.3.4.0 by 
Frontier Science Foundation-Hellas. The literature search 
was performed by the authors.
Results We report the presence of a gender gap within 
oncology. Results regarding the under-representation 
of women occupying leadership roles in oncology 
show female participation as members of the board or 
presidents of national and international oncology societies 
and as invited speakers at oncology congresses remains 
below 50% in the majority of societies included in this 
analysis. Women in leadership positions of societies was 
associated with a higher percentage of female invited 
speakers at these societies’ congresses (p=0.006).
Conclusion The full contribution that can be attained 
from using the potential of women in leadership roles is 
currently under-realised. Examples of how gender and 
minority participation in organisations improves outcomes 
and creativity are provided from science, clinical practice 
and industry that show outcomes are greatly improved 
by collective participation of both men and women. 
Although there are programmes in place in many oncology 
organisations to improve this disparity, the gender gap is 
still there. Ongoing discussion may help to create more 
awareness in the effort to accelerate the advancement of 
women within oncology.
IntRoduCtIon
The under-representation of women in lead-
ership roles is a theme that cuts across all 
sectors of society, including the global work-
force. While women comprise up to 42% of 
the world’s paid working population,1 it is 
estimated that just 24% of senior manage-
ment positions globally are occupied by 
women.2
Within the healthcare sector, women 
comprise over 75% of the workforce in many 
countries, making them an important factor 
in the delivery of medical services.1 Looking 
closer, it is important to note that there are 
imbalances at the professional level, where 
the nursing and midwifery professionals 
are nearly 90% women, while only 25% 
of physicians are women.3 It is crucial to 
create diversity in the healthcare workforce 
that mirrors the general population from a 
gender perspective and in general terms such 
as racial/ethnic backgrounds, people with 
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Key questions
How might this impact on clinical practice?
 ► Generally, groups having a mix that includes diverse backgrounds, 
nationalities and genders produce better outcomes. Women often 
exhibit a cooperative work style that enhances the effectiveness of 
groups, particularly when extensive information management and 
decision-making are required, such as treatment recommendations 
formulation. Women in leadership will contribute to a people-orient-
ed and interactive approach to the development and implementation 
of patient treatment policies. Policies developed by gender-balanced 
groups will encourage more women to practice oncology and will 
also reflect a female perspective that will benefit both male andfe-
male patients. The integration of women into all levels of oncology 
will ensure that the physician workforce reflects the gender diversity 
and cultural perception of the population it serves.
disabilities, as well as economically disadvantaged social 
backgrounds.4
A recent audit estimated that the field of oncology 
experienced a 3% increase in the number of oncologists 
per year from 2004 to 2011 in the USA. However, the 
same report set the number of women at 3716 (28.4%) 
in the composite oncologist physician workforce of 13 
084 for the year 2011.5 The representation of women in 
oncology may also be measured by their participation in 
national and international medical oncology societies, 
where women are achieving near parity with men in terms 
of membership. For example, in 2015, women comprised 
41.9% of the membership in the European Society for 
Medical Oncology (ESMO)6 while 36% of American 
Society of Clinical Oncology (ASCO) members as of 2016 
were women.7
ESMO membership statisticsi revealed that the number 
of active members had doubled, from 3788 in 2004 to 
7665 in 2012, and further increased by 2015–2016 to 13 
182, with the greatest rise seen in the percentage of female 
members, which rose from 24.9% to 35.2% to 40.5% 
during these years, respectively.8 This demographic shift 
prompted the ESMO president at that moment, Martine 
Piccart, to foster the Women for Oncology (W4O) initia-
tive in 2013, which started several audits of the female 
work force in oncology to identify challenges and rewards 
specific to female oncology professionals. This resulted 
in the ESMO Exploratory Study on the Challenges of 
Female Medical Oncologists that was presented at the 
European Cancer Congress 2013 in Amsterdam.9
W4O survey data presented at the ESMO 2016 Congress 
confirmed this trend; however, while the survey revealed 
that progress in parity is being achieved between genders 
on membership levels, it highlighted the persistent 
discrepancies in leadership positions within these soci-
eties and in the number of women invited to speak at 
i Data on ESMO membership might vary by a few percentage-
points at specific time points because of the evolving nature 
ofthe ESMO database. Nevertheless, this variation does not 
impacton the trends brought forth in this article.
major meetings. This account of gender disparity within 
leadership positions was consistent with similar statistics 
on women leaders throughout the global workforce as 
reported by the Global gender Gap Report 201610 as well 
as the WHO.1
This publication reports findings from the ESMO W4O 
data collection that presents a current view of the propor-
tion of women occupying leadership roles, including 
board members or presidents of medical oncology soci-
eties, and invited speakers at major oncology congresses. 
The basis of this report is an analysis of gender parity 
within ESMO that is expanded to a comparison with 
other major international societies, as well as figures from 
Asian, South American and European national societies.
The aim is to understand current gender disparities in 
oncology and to provide updated information revealing 
where strides forward have been taken and where change 
had stagnated in the journey towards achieving gender 
parity in oncology.
MetHods
This report is based on a database comprising data collec-
tion performed by ESMO, data analysis performed by 
Frontier Science Foundation-Hellas and a literature 
search performed by the authors.
Data were collected for the years 2015–2016, with 
2014 information used only when more recent data were 
unavailable. Information regarding the gender compo-
sition of oncology societies, both in absolute numbers 
and/or percentages, including board members and pres-
idents (for 2016), and congress speakers (for 2016–2015 
or if needed for 2014), was obtained via email queries. 
These were addressed to the society secretariat and/or 
the ESMO referent person who was also asked for infor-
mation on the criteria used to select the congress sessions. 
Regarding Asian national societies, only gender informa-
tion directly provided or confirmed by each society was 
included in the analysis. In the event that information 
regarding the gender of invited speakers was unavail-
able, the ESMO headquarters reviewed printed or online 
copies of the final congress programme book and derived 
gender information from the speakers’ names together 
with online biographies and/or photographs.
The analyses of presidency, board members and invited 
speakers included data from international societies and 
congresses as well as national European, South American 
and Asian societies and congresses.
European national societies were included on the 
basis of having an agreement of reciprocal membership 
with ESMO and Asian national oncology societies that 
endorsed the ESMO ASIA 2016 Congress (online supple-
mentary table 1). International congresses were selected 
on the basis of being organised by ESMO, the European 
CanCer Organisation (ECCO), American Society of Clin-
ical Oncology (ASCO), European Association for Cancer 
Research (EACR), American Association for Cancer 
Research (AACR), the European Society of Surgical 
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Table 1 Gender representation of ESMO board members 
(reference year 2016) and all ESMO members (reference 
year 2015)
Gender
ESMO board 
members—n (%)
ESMO members—n 
(%)
Male 12 (85.7) 7841 (59.5)
Female 2 (14.3) 5341 (40.5)
Total 14 (100.0) 13 182 (100.0)
ESMO, European Society for Medical Oncology.
Oncology (ESSO), European Organisation for Research 
and Treatment of Cancer (EORTC), the European Society 
for Radiotherapy and Oncology (ESTRO) and the Amer-
ican Society for Radiotherapy and Oncology (ASTRO). 
National European oncology congresses were chosen on 
the basis of being organised by national societies that had 
an agreement of reciprocal membership with ESMO.
Descriptive statistics of the female representation as 
board members and invited speakers were produced 
by society/congress name and geographical region. 
The correlations regarding the percentage of female 
board members or invited speakers versus the size of the 
society/congress and the percentage of female invited 
speakers versus the percentage of female board members 
are illustrated on a scatterplot. The Spearman correla-
tion coefficient was used to quantify the strength of those 
associations.
Basic descriptive statistics were produced regarding 
the constitution of ESMO membership for the year 2015, 
including summaries of member characteristics by age 
and gender. Fisher’s exact test or Mann-Whitney U test 
was used to determine the association between the gender 
composition of the ESMO Executive Board members and 
available characteristics of ESMO members.
A two-sided significance level of 0.05 was used for the 
statistical testing. All statistical analyses were performed 
using the Statistical Analysis Software V.9.3 and R language 
for statistical computing V.3.4.0.
Results
Gender composition of esMo membership and leadership
This analysis shows that gender demographics within 
ESMO are rapidly changing, with younger women repre-
senting the fastest growing segment of the membership. 
The proportion of women within ESMO membership 
has steadily grown from 20.2% in the year 2000 and has 
doubled according to figures for the year 2015. Evaluation 
of 13 082 ESMO members in 2015 revealed that women 
now represented 41.0% of members, with men contin-
uing to be the majority at 59.0% of the total membership.
Further analysis of membership records from the 12 
551 registered ESMO members having available age 
information showed that the majority (61.7%) of ESMO 
members were aged over 40 years, while the median age 
of all members was 44 years (range 22 to 97 years). Female 
members had a significantly lower median age compared 
with male members (41 years vs 47 years; p<0.001).
Looking more closely at the 4803 (38.3%) members 
aged 40 years or younger, there were 2489 (51.8%) women 
compared with 2314 (48.2%) men in this subgroup, which 
illustrates that the ESMO membership is growing signifi-
cantly quicker from the inclusion of younger women 
(p<0.001).
Table 1 depicts the gender composition of the ESMO 
Executive Board members (reference year 2016) and the 
total of ESMO members (reference year 2015). Out of the 
14 ESMO board members, only 2 (14.3%) were women, 
while of the 13 182 ESMO members, 5341 (40.5%) were 
women.
Comparison of the number of women board members of 
oncology societies
The presidency and board member analysis comprised 
data from the nine international societies listed in online 
supplementary table 1 (AACR, ASCO, ASTRO, EACR, 
ECCO, EORTC, ESMO, ESSO, ESTRO) and 44 national 
societies (21 European, 6 South American and 17 Asian.
Despite a clear trend towards an increase of women 
within the field of oncology and among the ranks of 
ESMO, women continue to be under-represented in 
senior roles within this organisation. Under-represen-
tation of women in leadership positions such as board 
members or presidents in oncology societies was reflected 
across most of the societies evaluated in this study. This 
analysis included the number of current board members 
during 2016, excluding society presidents who have 
been analysed separately. Ex-officio board members and 
members with no voting rights were also included in the 
analysis.
Overall, in 2016, 29 out of the 115 (25.2%) board 
members of all of the international societies reviewed 
were female oncologists, which does not differ signifi-
cantly from the 27.5% (265 women out of a total of 962 
board members) of Asian, European and South Amer-
ican national societies (p=0.66). Additionally, within 
the international societies there was no significant 
difference between the European-based (24.2% women 
board members) versus US-based (26.5%) societies 
(p=0.83).
The representation of women as board members 
in ESMO was not different from the representation 
of women oncologists on the boards of the other 
eight international societies (all p>0.1). However, 
the percentage of women named as oncology board 
members ranged from 7.1% for ASTRO to 46.7% 
for AACR. In general, societies with an emphasis on 
research had the highest percentage of women occu-
pying board positions, including AACR (46.7%), EACR 
(40.0%) and EORTC (28.6%), as compared with more 
clinically oriented organisations, such as ESMO (14.3%) 
and ASCO (25.0%) (figure 1).
A significant variation between the gender composition 
of national boards (reference year 2016) was observed 
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Figure 1 Gender representation of board members in 
all international societies (reference year: 2016). AACR, 
American Association for Cancer Research; ASCO, 
American Society of Clinical Oncology; ASTRO, American 
Society for Radiotherapy and Oncology; EACR, European 
Association for Cancer Research; ECCO, European CanCer 
Organisation; EORTC, European Organisation for Research 
and Treatment of Cancer; ESMO, European Society for 
Medical Oncology; ESSO, European Society of Surgical 
Oncology; ESTRO, European Society for Radiotherapy and 
Oncology.
between European, South American and Asian national 
oncology boards (p=0.039). The European national soci-
eties had a higher percentage of female board members 
(33.8%) compared with the Asian (24.8%) and the South 
American (27.7%) national societies.
The majority of almost all society boards consisted 
of men. For all societies with large board size (N>20), 
more than 60% of the members were men. Only six 
societies had more female than male board members; 
of these, two were Asian (MyOS: 72% women, N=18; 
PSMO: 56%, N=9), one was South American (SOMPU: 
64%, N=11) and three were European (AIOM: 57%, 
N=7; MAGYOT: 80%, N=5; UMOS: 60%, N=5).
The percentage of female board members of Euro-
pean national societies varied from 0% for the OEGHO 
to 80% for the MAGYOT.
On review of Asian and South American national 
societies, a strikingly disparate range for the proportion 
of female board members emerged, from 0% for the 
AOU or SLACOM, to 72% of the MyOS and 64% in the 
SOMPU boards.
It should be noted that the percentage of women acting 
as board members showed an association with the size 
of the society, which approached statistical significance 
(p=0.051).
Representation of women as presidents of oncology societies
As could be anticipated with women being under-repre-
sented at the board member level, few oncology societies 
had women presidents. In 2016, of the 53 international 
and national societies analysed, 48 (90.6%) presidents 
were men, with just 5 (9.4%) female presidents.
An apparent but not statistically significant association 
was observed between having a female president and 
the percentage of women board members of societies; 
societies having a female president also had 38.2% of 
women board members, whereas 26.6% of women occu-
pied board positions in societies having a male president 
(p=0.084).
The direction of this association, even though non-sig-
nificant, suggests that the integration of women into the 
boards of societies opens the door to placement in addi-
tional leadership positions.
Representation of women as invited speakers at oncology 
congresses
A third indicator of the assimilation of women into leader-
ship roles within the field of oncology is their representa-
tion as invited speakers at national and international 
congresses.
The analysis of invited speakers represented data from 
6 international congresses (AACR, ASCO, EACR, ECCO, 
ESMO, ESSO), 9 European national congresses, 3 South 
American national congresses and 17 Asian national 
congresses held during 2015–2016.
Overall, women represented less than one-third 
of invited speakers. Out of the total of 5496 invited 
speakers, 3876 (70.5%) were men and 1620 (29.5%) were 
women. Women remained under-represented as speakers 
compared with men at the international and all national 
(European, South American and Asian) congresses 
assessed.
There was no difference when comparing female repre-
sentation as invited speakers in all international (30.3%) 
versus in all national congresses (28.9%) (p=0.27).
However, focusing only on the international congresses, 
a direct comparison of American-based versus Europe-
an-based international congresses revealed a greater 
proportion of women speakers at American-based 
(33.1%) versus European-based (27.5%) international 
congresses (p=0.004) (analytical percentage by congress 
shown in figure 2).
As shown in table 2, within the major international 
congresses held during 2016, women represented approx-
imately one-third of invited speakers at most congresses 
(32.4% AACR, 34% ASCO and 32.9% ECCO). Lower 
representation was seen in EACR, ESMO and ESSO, 
where women represented 27.5%, 26.2% and 10.9%, 
respectively, of the invited speakers at the respective 
congresses.
The representation of women as speakers at national 
congresses also differed significantly from 24.4% in Asian 
versus 33.5% in European versus 34.4% in South Amer-
ican congresses (p<0.0001).
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Figure 2 Gender representation in all international 
congresses (reference year 2016). AACR, American 
Association for Cancer Research; ASCO, American Society 
of Clinical Oncology; EACR, European Association for 
Cancer Research; ECCO, European CanCer Organisation; 
ESMO, European Society for Medical Oncology; ESSO, 
European Society of Surgical Oncology.
Table 2 Comparison of the percentage of women as 
invited speakers between the ESMO congress and other 
international congresses (reference year 2016)
Comparison P values
ESMO (N=588) vs Europe-based congresses
  ESMO vs ECCO (N=422) (26.2% vs 32.9%) 0.021
  ESMO vs EACR (N=69) (26.2% vs 27.5%) 0.77
  ESMO vs ESSO (N=91) (26.2% vs 10.9%) 0.001
ESMO (N=588) vs US-based congresses
  ESMO vs ASCO (N=485) (26.2% vs 34.0%) 0.006
  ESMO vs AACR (N=683) (26.2% vs 32.4%) 0.019
Bold values indicate where the p value is significant.
AACR, American Association for Cancer Research; ASCO, 
American Society of Clinical Oncology; EACR, European 
Association for Cancer Research; ECCO, European CanCer 
Organisation; ESMO, European Society for Medical Oncology; 
ESSO, European Society of Surgical Oncology.
Figure 3 Scatterplot of the percentage of female invited 
speakers versus the percentage of female board members. 
Note: Societies DGHO and OEGHO constitute one 
category/society. Please see appendix for definitions of 
abbreviations.
While the proportion of women invited speakers 
at congresses was not associated with the size of the 
congress (p=0.47), a high participation by women as 
board members of oncology societies seemed to trans-
late to greater representation of women as speakers at 
congresses. A significant positive association was found 
between the percentage of women members of oncology 
society boards and the percentage of women invited 
speakers at congresses organised by these societies 
(p=0.006). This association was based on 32 societies 
having available information for both invited speakers 
and board members (figure 3).
To illustrate this point, in 2016 AACR had a female 
president, 47% of board members were women and 
the AACR congress had one of the higher percentages 
(32%) of female speakers. Among European national 
societies, the UMOS board comprised 60.0% women and 
the highest percentage (72%) of female speakers at their 
congress. A high proportion (47.0%) of female speakers 
was observed in the MyOS and MOGA (41%) congresses, 
which was reflected in board member female composi-
tion of 72% and 50%, respectively.
dIsCussIon
This report demonstrates the existence of a gender gap 
that is not narrowing within the leadership in oncology. 
Although women are entering the field and participating 
as members of oncology societies, this has not translated 
into more women occupying positions as board members, 
presidents of these societies or as invited expert speakers 
at congresses organised by international and national 
oncology societies. The gender composition of oncology 
society boards impacts the representation of women as 
invited speakers; however, the female membership of a 
society does not seem to be a factor in the number of 
women invited as congress speakers.
Women currently constitute the majority of ESMO 
members under the age of 40, but they continue to occupy 
a very small percentage of leadership positions within 
ESMO and most other oncology societies. In 2016, just 
2 (14.3%) of the 14 ESMO board members were women.
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Further, a survey of several well-known US academic 
journals revealed that 5.9% of first authors in 1970 were 
women, while 29.3% female first-authors published in 
2004 (p<0.001). A last author comparison showed 3.7% 
were women in 1970 and 19.3% in 2004. Additionally, 
only 1.5% of guest editorials were authored by women 
in 1970, which rose to the tiny proportion of 11.4% by 
2004.11
A growing body of evidence demonstrates that individ-
uals with diverse backgrounds increase both innovation 
and creativity within groups.12 Taking an example from 
the corporate world, financial performance was improved 
in gender-diverse teams, which outperformed non-di-
verse teams in terms of average economic growth, return 
on equity, debt/equity ratios, greater market share, 
higher sales revenue and increased profits overall.13 One 
analysis found that race-based and gender-based diversity 
improved economic growth but was important in under-
standing human interactions.14
The need for gender parity at all levels of organisations 
is nowhere as apparent as within medical science, where 
collaborative working groups that are gender heteroge-
neous produce better quality science.15 Gender parity in 
leadership comes closest to being attained in research-ori-
ented oncology societies, for example, AACR and EACR, 
which have female board representation of 46.7% and 
40.0%, respectively. In addition, AACR has the only 
female president among international societies, as well as 
a female CEO, identified by this audit. In contrast, the 
SLACOM, OEGHO, AOU, JSCO, JSMO and the HKCTS 
had no female representation on their boards within the 
reference period of this article.
The importance of having equal female representation 
in the oncology physician workforce was underscored in 
a recent paper, which pointed out that women practice 
medicine differently than men and are more likely to 
adhere to clinical guidelines. These investigators found 
that patients treated by female physicians had lower 30-day 
mortality rates (p<0.001) and fewer 30-day readmissions 
(p<0.001) than patients treated by male physicians.16
The proportion of elderly in the global populations is 
rapidly increasing17 and, together with treatment advances, 
means that more patients will need care for chronic 
conditions and more healthcare professions, particularly 
in oncology, will be needed. A recent audit disclosed that 
within the USA, the median age of oncologists was higher 
than that of physicians overall and a large proportion of 
practising oncologists were older than 65 years. However, 
they also found fewer women enter the oncology field.5 
Female patients may benefit from receiving medical treat-
ment from female clinicians, and this advantage should 
also be extended to women, who comprise approximately 
50% of the oncology population.18 It has been noted that 
both men and women show gender preferences, particu-
larly for intimate examinations.19
Oncology includes women and men of diverse races, 
ethnicities and cultures working towards the common 
goal of providing optimal care for patients with cancer. 
Inclusion of women in international guideline devel-
opment improves gender responsiveness of the health-
sector workforce, making panel member diversity key in 
producing guidelines that are relevant to patient-specific 
considerations.20
A survey brought forward by the W4O Committee 
reported that the lack of work–family balance was cited as 
the main barrier to achieving gender parity in leadership 
roles by 52.8% of male and female respondents. Percep-
tion-based barriers to leadership also carried importance, 
with 39.9% and 22.8% of female participants responding 
that men are perceived as natural leaders while women 
are perceived more as a team members and supporters, 
and that cultural gender prejudice exists due to miscon-
ceptions about family and domestic responsibilities of 
women, respectively.21
These findings are supported by a survey of academic 
clinical department chairs who cited the constraints of 
traditional gender roles, manifestations of sexismin the 
medical environment, and lack of effective mentors as 
elements affecting the integration of women into leader-
ship roles at universities. They also raised the possibility 
that women may devote more time to teaching and clin-
ical activity.22
Overcoming internalised or unconscious bias mani-
fested by both genders remains an intangible challenge 
that affects women and prevents some from seeking senior 
positions. Women may be regarded as less competent 
than men, even when their experience and qualifications 
are equivalent.23 Women must contend with behavioural 
double standards that describe men striving for leader-
ship positions as ‘ambitious and direct’, whereas women 
exhibiting the same behaviours are labelled ‘bossy or 
rude’.24 It is important to note that implicit gender bias 
favouring men does not necessarily arise from explicitly 
held beliefs, with many people being genuinely unaware 
that this bias or generally stereotypes are affecting their 
decisions.25
The W4O Committee is taking steps to stimulate diver-
sity regarding gender and also including individuals of 
different races, social backgrounds and those with phys-
ical disabilities. ESMO, the reference oncology society 
used here, is not alone in providing preceptorship, 
mentor, sponsor and leadership programmes.
Aiming to overcome the barriers of work–life balance 
and ensuring family-friendly frameworks, ESMO has 
begun to provide day-care during the larger ESMO 
congresses so participants can benefit from educational 
and networking activities while knowing their children 
are cared for by qualified adults.
Other programmes are in place to support members in 
career advancement with advice provided by a gender-di-
verse faculty. Gender balance has already been achieved 
in the ESMO Leaders Generation Programme of 2017, 
which comprises eight female and seven male oncologists 
who learnt the skills for successful leadership.
In addition to these programmes, ESMO also provides 
fellowships consisting of financial and professional 
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support. Although women and men are equally encour-
aged to apply, the recipients in 2017 in clinical research 
were all men, whereas the translational research fellow-
ships were women. Among the recipients of palliative 
care fellowships, six of eight were men and all were of 
diverse nationalities. ESMO may help in decreasing this 
gender disparity by ensuring men and women get the 
same opportunities.
The Annual Gender Gap Report of the World Economic 
Forum recently made a call for action to work on gender 
parity by revising its previous target estimate of globally 
achieving gender parity in pay and job opportunities from 
80 years to over 170 years. They attribute this ‘glacial pace 
of change’ largely to unconscious bias.26 This unconscious 
bias must be countered by conscious attempts through 
sponsorship and mentorship programmes offering 
support to women and other under-represented groups.
Taking everything together, in oncology societies, 
especially ESMO, female membership is continuously 
growing. However, we must not automatically conclude 
from this that women will evolve over time to occupy 
leadership roles. In fact, a comparison of the number 
of female board members in 2014 with 2017 shows no 
change whatsoever has taken place.
Although the examples provided in this publication 
originate from ESMO initiatives, they are indicative of 
activities being pursued to varied degrees by many of the 
oncology societies today. They represent the necessary 
first steps towards providing mentorship and advance-
ment initiatives for women and to incorporate women 
into all levels of oncology. As the pace of progress is 
slow, highlighting more rigorous action is needed. Over-
coming conscious and unconscious biases that contribute 
to gender as well as other inequalities through training 
to recognise unconscious bias, nurturing, inclusiveness 
and consistency regardless of society, gender or ethnicity 
will be the accelerant to fuel the rapid change needed to 
reach this goal within our lifetime.
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